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Introduction: Tumor invasion in lung adenocarcinoma is defined 
as infiltration of stroma, blood vessels, or pleura. Based on obser-
vation of tumor spread through air spaces (STAS), we considered 
whether this could represent new patterns of invasion and investi-
gated whether it correlated with locoregional versus distant recur-
rence according to limited resection versus lobectomy.
Methods: We reviewed resected small (less than or equal to 2 cm) 
stage I lung adenocarcinomas (n = 411; 1995–2006). Tumor STAS 
was defined as tumor cells—micropapillary structures, solid nests, 
or single cells—spreading within air spaces in the lung parenchyma 
beyond the edge of the main tumor. Competing risks methods were 
used to estimate risk of disease recurrence and its associations with 
clinicopathological risk factors.
Results: STAS was observed in 155 cases (38%). In the limited 
resection group (n = 120), the risk of any recurrence was signifi-
cantly higher in patients with STAS-positive tumors than that of 
patients with STAS-negative tumors (5-year cumulative incidence of 
recurrence, 42.6% versus 10.9%; P < 0.001); the presence of STAS 
correlated with higher risk of distant (P = 0.035) and locoregional 
recurrence (P = 0.001). However, in the lobectomy group (n = 291), 
the presence of STAS was not associated with either any (P = 0.50) or 
distant recurrence (P = 0.76). In a multivariate analysis, the presence 
of tumor STAS remained independently associated with the risk of 
developing recurrence (hazard ratio, 3.08; P = 0.014).
Conclusion: The presence of STAS is a significant risk factor of 
recurrence in small lung adenocarcinomas treated with limited resec-
tion. These findings support our proposal that STAS should formally 
be recognized as a pattern of invasion in lung adenocarcinoma.
Key Words: Lung, Adenocarcinoma, Invasion, Spread through air 
spaces, Recurrence.
(J Thorac Oncol. 2015;10: 806–814)
Lung adenocarcinoma invasion is traditionally defined as: (1) the presence of nonlepidic patterns such as acinar, papil-
lary, solid, or micropapillary; (2) infiltration of stroma; and (3) 
infiltration of blood vessels or structures such as the visceral 
pleura.1 During our studies of the pathologic characteristics 
of lung adenocarcinoma,2–8 we noticed tumor cells spreading 
in air spaces into the lung parenchyma adjacent to the edge of 
the tumor. We named this phenomenon “spread through air 
spaces” (STAS) and define it as spread of lung cancer tumor 
cells into air spaces in the lung parenchyma adjacent to the 
main tumor. Literature review revealed multiple studies of 
various cancers in the lung that have presented with this fea-
ture reported using different terms, some of which have shown 
associations with poor prognosis.9–12 Until now, this problem 
has received surprisingly little attention in the pathology liter-
ature, and the clinical implication of its presence in pathologi-
cal specimens is not well appreciated. Therefore, using a large 
cohort of patients with resected small (less than or equal to 
2 cm) stage I lung adenocarcinoma, we investigated whether 
tumor STAS was a risk factor of disease recurrence according 
to types of surgical procedures (lobectomy or limited resec-
tion) and location of recurrence (locoregional or distant).
PATIENTS AND METHODS
Patient Cohorts
This retrospective study was approved by Memorial 
Sloan Kettering Cancer Center’s Institutional Review Board. 
Pathologic stage determination was based on the 7th edi-
tion of the American Joint Committee on Cancer Staging 
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Manual.13 We reviewed patients with lung adenocarcinomas 
that had been surgically resected and diagnosed as small (less 
than or equal to 2 cm), pathological stage I disease between 
1995 and 2006. Cases with neoadjuvant therapy, multiple 
nodules, positive surgical margin, other lung cancer sur-
gery within the past 2 years, other disease progression, and 
no available tumor slides for review were excluded from the 
study cohort. According to these criteria, we identified a total 
of 411 patients. Although a subset of these cases have been 
published in our previous publications,2–8 the medical records 
and database were reviewed to update patients’ follow-up as 
of March 2014. All recurrences were confirmed by clinical, 
radiological, or pathological assessment, and were classified 
into locoregional (local + regional) and distant recurrence.7,14 
Local recurrence was defined as evidence of a tumor in the 
same lobe or at the surgical margin of the original tumor. 
Regional recurrence was defined as evidence of a tumor in a 
second ipsilateral lobe, in the ipsilateral hilar lymph nodes, or 
in the ipsilateral mediastinal lymph nodes. Distant recurrence 
was defined by evidence of a tumor in the contralateral lung, 
in the contralateral mediastinal, in the ipsilateral supraclavicu-
lar lymph nodes, or outside the hemithorax.
Histologic Evaluation
Tumor slides from the internal training cohort were 
reviewed by two pathologists (K.K. and W.D.T.), who were 
blinded to patient clinical outcomes; they used an Olympus 
BX51 microscope (Olympus Optical Co. Ltd., Tokyo, Japan) 
with a standard 22-mm diameter eyepiece.
Tumor STAS was defined as tumor cells within air spaces 
in the lung parenchyma beyond the edge of the main tumor 
(Fig. 1A and D) and was composed of three morphological 
patterns: (1) micropapillary structures consisting of papillary 
structures without central fibrovascular cores (Fig. 1A and 
B),15,16 which occasionally form ring-like structures within air 
spaces (Fig. 1C); (2) solid nests or tumor islands consisting of 
solid collections of tumor cells filling air spaces (Fig. 1D and 
E)17; and (3) single cells consisting of scattered discohesive 
single cells (Fig. 1F). The edge of the main tumor was defined 
as the smooth surface of the tumor which is easily recogniz-
able at gross or at low-power field examination as highlighted 
with the dotted line in Figure 1A. Tumor STAS was considered 
present when tumor STAS, as defined above, was identified 
beyond the edge of the main tumor even if it existed only in 
the first alveolar layer from the tumor edge. Lesions of STAS 
consist of tumor cells which morphologically appear to be sit-
uated within air spaces as micropapillary clusters, solid nests 
or single cells that are detached from alveolar walls. This dif-
fers from lepidic growth where tumor cells grow in a linear 
fashion along the surface of alveolar walls. Extent of air space 
filling by tumor cells varied from abundant cellular infiltrates 
to very inconspicuous single cells or micropapillary clusters 
that were sometimes difficult to distinguish from alveolar 
macrophages. In addition, distance between tumor surface 
and farthest STAS from tumor edge was measured by a ruler. 
Because lung specimens were not consistently inflated during 
processing, to account for artifactual atelectasis, we also mea-
sured according to the number of alveolar spaces.
Tumor cells of STAS were distinguished from alveolar 
macrophages using the following methods. Macrophages in 
smokers typically have cytoplasm containing faint brown pig-
ment and black carbon granules, whereas in nonsmokers the pig-
ment is lacking and cytoplasm is sometimes foamy. Nuclei are 
small, uniform, and regular, without atypia. Nuclear folds are 
frequent and nucleoli are inconspicuous or absent. In contrast, 
FIGURE 1.  Morphologic features of tumor STAS pattern (original magnification: ×20 in A and D; ×200 in B, C and E; ×400 
in F). A, Micropapillary pattern STAS (arrows) identified within air spaces in the lung parenchyma beyond the edge (dashed 
line) of the main tumor. B, Micropapillary pattern STAS consisting of papillary structures without central fibrovascular cores. C, 
Micropapillary pattern STAS forming ring-like structures within air spaces. D, Solid pattern STAS identified within air spaces in 
the lung parenchyma beyond the edge of the main tumor. E, Solid type STAS consisting of solid collections of tumor cells filling 
air spaces. F, Single cell pattern STAS consisting of scattered discohesive single cells (arrows). STAS, spread through air spaces.
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tumor cells of STAS typically lack cytoplasmic pigment or 
foamy cytoplasm. They often grow in cohesive clusters and 
nuclei are atypical with hyperchromasia and frequent nucleoli. 
The distinction of STAS from artifacts was done in the following 
way. Tumor floaters were favored, by the presence of clusters of 
cells often randomly scattered over tissue and at the edges of the 
tissue section. The presence of jagged edges of tumor cell clus-
ters suggested tumor fragmentation or edges of a knife cut dur-
ing specimen processing rather than STAS. Linear strips of cells 
that were lifted off of alveolar walls also favored the presence of 
artifact. Identification of tumor cells distant from the main tumor 
was regarded as an artifact unless intraalveolar tumor cells could 
be demonstrated in a continuum of airspaces containing intraal-
veolar tumor cells back to the tumor edge.
According to the International Association for the Study 
of Lung Cancer, American Thoracic Society, and European 
Respiratory Society histological classification, the percentage 
of each histologic pattern—lepidic, acinar, papillary, solid, 
and micropapillary—was recorded in 5% increments and 
tumors were classified by their predominant pattern.1 Each 
histologic pattern was considered present in the tumor when 
it comprised greater than or equal to 5% of the overall tumor.7 
The presence of visceral pleural, lymphatic, and vascular inva-
sion was also recorded.
Statistical Analysis
Associations between variables were analyzed using 
Fisher’s exact test (for categorical variables) and the Wilcoxon 
test (for continuous variables). The risk of developing dis-
ease recurrence was analyzed using competing risks methods. 
Cumulative incidence of recurrence (CIR) of any kind (locore-
gional or distant) was estimated using a cumulative incidence 
function that accounted for death without recurrence as a com-
peting event.18,19 In addition, for the analyses investigating the 
risk of disease recurrence according to the locations, distant or 
locoregional recurrence was considered as a second type of com-
peting risk. Follow-up was calculated from date of surgery to date 
of disease recurrence, death from any cause, or last follow-up. 
Differences in CIR between groups were assessed using Gray’s 
test (for univariate nonparametric analysis) and Fine-Gray com-
peting risk model (for multivariate analysis) after the adjustment 
for important potential confounders.19,20 Overall survival (OS) 
was estimated using the Kaplan–Meier method, and nonparamet-
ric group comparisons were performed using the logrank test.
All P values were based on two-tailed statistical anal-
ysis and P value less than 0.05 was considered statistically 
significance. Statistical analyses were conducted using SAS 
version 9.2 (SAS Institute, Cary, NC) and R (version 3.0.1; 
R Development Core Team), including the “survival” and 
“cmprsk” packages.
RESULTS
Patient Characteristics and Their Associations 
with Recurrence
Of all, 120 patients underwent limited resection (wedge 
resection [n = 82] and sublobectomy [n = 38]) and 291 under-
went lobectomy. In limited resection group, 68 patients (57%) 
underwent lymph node dissection or sampling, whereas in 
lobectomy group, all patients underwent lymph node dissec-
tion or sampling. In the limited resection group, 28 patients 
(23%) experienced recurrence (locoregional [n = 14] and dis-
tant [n = 14]) and 37 patients (31%) died from any cause with-
out documented recurrence; median follow-up for patients 
who did not experience recurrence was 88.4 months (range, 
0.2–202.6 months). In the lobectomy group, 30 patients (10%) 
experienced recurrence (locoregional [n = 6] and distant 
[n = 24]) and 62 patients (21%) died from any cause without 
documented recurrence; median follow-up for patients who 
did not experience recurrence was 77.5 months (range, 0.6–
190.6 months). Patient characteristics and their associations 
with CIR, according to types of surgery, are shown in Table 1. 
In the limited resection group, patient age (P = 0.046), tumor 
size (P = 0.004), lymphatic invasion (P = 0.001), and vas-
cular invasion (P = 0.005) were risk factors for recurrence. 
In the lobectomy group, patient age (P = 0.022), lymphatic 
invasion (P = 0.003), vascular invasion (P = 0.005), and pre-
dominant histologic subtypes (P = 0.006) were risk factors for 
recurrence.
Association between Clinicopathologic Factors 
and STAS
STAS was observed in 155 cases (38%). When clas-
sifying tumors according to predominant pattern of STAS, 
there were 94 tumors with micropapillary STAS, 53 with 
solid STAS, and eight with single cell STAS. Associations 
between clinicopathologic factors and STAS are summarized 
in Table 2. Lymphovascular invasion and high-grade mor-
phologic pattern in main tumors were more frequently identi-
fied in STAS-positive tumors than in STAS-negative tumors: 
lymphatic invasion (42% versus 27%; P = 0.002), vascular 
invasion (28% versus 19%; P = 0.043), micropapillary pat-
tern (83% versus 30%; P < 0.001), and solid pattern (46% 
versus 30%; P = 0.001). In contrast, lepidic pattern was less 
frequently identified in STAS-positive tumors than in STAS-
negative tumors (50% versus 69%; P < 0.001).
Distance of Tumor STAS from Edge of Main 
Tumor
Distance between tumor surface and farthest STAS 
from the tumor edge was measured by a ruler with a median 
of 1.5 mm (range, 0.2–8.5 mm; Fig. 2A). We also measured 
according to the number of alveolar spaces (median, 7; range, 
1–58; Fig. 2B). Although we defined tumor STAS as tumor 
cells identified within air spaces beyond the tumor edge even 
if it existed only in the first alveolar layer, in 97% (n = 151) of 
the STAS-positive cases, tumor STAS was located beyond the 
first alveolar layer from the tumor edge (range, 2–58). Using 
an approximate alveolar size of 0.3 mm (range, 0.2–0.5 mm), 
we estimate a maximum distance of 1.7 cm for STAS found 
away from the tumor edge.
Risk of Recurrence by Tumor STAS According to 
Types of Surgery and Locations of Recurrence
In limited resection group, the risk of develop-
ing any types (locoregional or distant) of recurrence was 
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significantly higher in patients with STAS-positive tumors 
than in patients with STAS-negative tumors (5-year CIR, 
42.6% versus 10.9%; P < 0.001; Fig. 3A). In multivariate 
analysis, the presence of tumor STAS was an independent 
and the only risk factor of any recurrence (hazard ratio, 
3.08; P = 0.014; Table 3). However, in the lobectomy 
group, the presence of tumor STAS was not associated 
with an increased risk of any recurrence, compared with 
the absence of STAS (5-year CIR, 12.7% versus 9.5%; 
P = 0.50; Fig. 4A).
Among patients who underwent limited resection, 
patients with STAS-positive tumors had a significantly 
increased risk of developing distant recurrences, compared 
with patients with STAS-negative tumors (5-year CIR, 
20.4% versus 6.8%; P = 0.035; Fig. 3B). In contrast, in the 
lobectomy group, the presence of tumor STAS was not asso-
ciated with an increased risk of distant recurrence, compared 
with the absence of STAS (5-year CIR, 9.6% versus 7.6%; 
P = 0.76; Fig. 4B).
Similarly, in the limited resection group, patients with 
STAS-positive tumors had a significantly increased risk of 
developing locoregional recurrences, compared with patients 
with STAS-negative tumors (5-year CIR, 22.2% versus 4.1%; 
P = 0.001; Fig. 3C).
OS by Tumor STAS According to Types of 
Surgery
Among patients who underwent limited resection, 
STAS-positive tumors was significantly associated with worse 
OS, compared with STAS-negative tumors (5-year OS, 59.3% 
[95% CI: 46.4–75.8] versus 75.1% [95% CI: 65.7–85.8]; 
P = 0.001). Among patients who underwent limited resection, 
although the association of OS with STAS (presence versus 
absence) was statistically significant (P = 0.045), the differ-
ence of 5-year OS rates between STAS-positive and STAS-
negative patients was minimal (83.9% [95% CI: 76.9–91.5] 
versus 88.6% [95% CI: 83.9–93.6]).
TABLE 1.  Clinicopathologic Associations with Recurrence According to Types of Surgery
Variables
Limited Resection Group (n = 120) Lobectomy Resection Group (n = 291)
n (%) 5-Yr CIR% 95% CI P n (%) 5-Yr CIR% 95% CI P
Age, years 0.046 0.022
  <65 41 (34) 34.2 22.2–52.7 127 (44) 15.3 10.0–23.5
  ≥65 79 (66) 17.1 10.4–28.1 164 (56) 7.1 4.0–12.6
Sex 0.40 0.22
  Women 73 (61) 19.8 12.3–31.8 174 (60) 8.7 5.2–14.3
  Men 47 (39) 27.8 17.4–44.5 117 (40) 13.6 8.5–21.9
Smoking 0.79 0.25
  Never 15 (13) 20.6 7.2–59.1 37 (13) 5.7 1.4–22.3
  Former/current 105 (88) 23.3 16.4–33.2 254 (87) 11.5 8.0–16.4
Tumor size 0.004 0.64
  ≤1.0 cm 35 (29) 5.9 1.5–23.1 50 (17) 12.9 6.0–27.6
  >1.0 cm 85 (71) 29.9 21.4–41.6 241 (83) 10.2 6.9–15.1
Pleural invasion 0.87 0.13
  Absent 102 (85) 23.1 16.1–33.2 262 (90) 9.9 6.7–14.4
  Present 18 (15) 22.2 9.1–54.4 29 (10) 17.4 7.7–39.2
Lymphatic invasion 0.001 0.003
  Absent 75 (63) 13.7 7.6–24.5 202 (69) 7.0 4.1–11.8
  Present 45 (38) 38.6 26.5–56.4 89 (31) 19.2 12.3–29.9
Vascular invasion 0.005 0.005
  Absent 96 (80) 17.1 10.9–26.8 223 (77) 7.8 4.9–12.5
  Present 24 (20) 45.8 29.2–72.0 68 (23) 20.0 12.2–32.8
Histologic subtype 0.22 0.006
  AIS + MIA 3 (3) 0.0 NA 6 (2) 0.0 NA
  Lepidic 18 (15) 6.4 0.9–45.7 20 (7) 5.0 0.7–35.5
  Acinar 49 (41) 31.2 20.4–47.8 145 (50) 8.2 4.6–14.5
  Papillary 24 (20) 29.2 15.3–55.5 66 (23) 8.3 3.6–19.4
  Micropapillary 8 (7) 25.0 6.9–90.9 10 (3) 20.0 5.3–75.4
  Solid 16 (13) 13.0 3.4–50.5 36 (12) 30.2 17.7–51.4
  Othersa 2 (2) NA NA 8 (3) NA NA
Significant P values are shown in bold.
aOthers include invasive mucinous and colloid predominant adenocarcinomas.
CIR, cumulative incidence of recurrence; CI, confidence interval; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; NA, not applicable.
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DISCUSSION
In this study, we have shown that STAS was a signifi-
cant prognostic factor for distant and locoregional recurrence 
in patients undergoing limited resection. We found this in 
almost 40% of resected lung adenocarcinomas and observed 
tumor cells over 1 cm away from the edge of the tumor. This 
observation is the primary basis for our proposal that STAS 
be formally recognized as a pattern of invasion in lung adeno-
carcinoma. STAS is an insidious pattern of invasion because 
it is not visible to pathologists on gross exam and to surgeons 
on external examination of the tumor specimen at the time of 
surgery, and we are unaware of any method of radiologically 
detecting it.
There were several reasons why this pattern has not 
been previously accepted as a form of invasion. First, this 
pattern of invasion is unique to the lung compared with other 
organs because lung anatomy differs due to the presence of 
air spaces, which normally contain air but also provide a 
path through which tumor cells can spread. Second, STAS is 
easily dismissed as an artifact where cells within air spaces 
were regarded as floaters or carry over due to contamina-
tion during processing. Because pathologists are not trained 
to look for these cells in the lung parenchyma beyond the 
edge of lung adenocarcinomas, STAS is mostly overlooked 
on microscopic review. Furthermore, due to paucity of data, 
there has been little emphasis on the clinical significance of 
this finding, and pathologists have not been compelled to 
look for this routinely.
Review of the literature revealed several sources of data 
that also support our proposal. First, studies of angiogenesis 
in lung cancer have classified tumors according to several 
different patterns of growth including alveolar patterns that 
correlated significantly with poor outcome.9 In context of 
investigations primarily focused on lung cancer angiogenesis, 
it was shown that alveolar pattern of spread was nonangio-
genic in contrast with other patterns of invasion which were 
angiogenic.21 Second, Onozato et al. studied the solid nest 
form of STAS (calling them “tumor islands”) with 3D recon-
struction using an automated tissue sectioning machine. They 
demonstrated that tumor islands were interconnected with 
each other and connected to solid areas in the adjacent main 
tumor.22 This study was followed by a clinical study that indi-
cated a worse prognosis for patients whose tumors had tumor 
islands.17 Third, radiation therapists have been interested in 
“microscopic extension” in lung cancers and have emphasized 
the importance of clinical target volume or areas of subclini-
cal involvement around gross tumor volume, as they design 
accurate radiation dose delivery.23–26 They pointed out that 
these microscopic extensions spread in increasing amounts up 
to over 1 cm beyond the grossly visible edge of tumor, very 
similar to our observations.23–26 In several articles on the topic 
of “microscopic extension,” pathology figures illustrated typi-
cal examples of what we proposed to label STAS.23,24 Fourth, 
the adverse impact of the STAS-like pattern has not only 
been demonstrated in lung cancer but also in colon cancer 
metastatic to the lung where patients whose metastatic tumors 
showed that this feature had worse prognosis compared with 
those that did not have this feature.10,11,27 Finally, although the 
historical term aerogenous spread could be considered for 
STAS, it was used in the context of the old concept of bron-
chioloalveolar carcinoma, most of those cases consisted of 
lepidic growth, which is different from the intraalveolar local-
ization of STAS.12
Identification of tumor cells within air spaces and 
detached from the adjacent alveolar walls in histologic sections 
raised important issues in the differential diagnosis. First, one 
can ask whether tumor cells were completely detached and 
floating within the air space or if they had an attachment to 
an alveolar wall. Onozato et al.17 showed that “tumor islands” 
TABLE 2.  Associations between Clinicopathologic Factors 
and Tumor STAS
Variables
All Patients
STAS
Absent Present
Pn (%) n (%) n (%)
Age, years 0.090
Median 68 68 67
Range 28–89 28–89 36–87
Sex 0.22
  Woman 247 (60) 148 (58) 99 (64)
  Men 164 (40) 108 (42) 56 (36)
Smoking 0.62
  Never 52 (13) 34 (13) 18 (12)
  Former/current 359 (87) 222 (87) 137 (88)
Surgery 0.87
  Lobectomy 291 (71) 182 (71) 109 (70)
  Limited resection 120 (29) 74 (29) 46 (30)
Tumor size, cm 0.71
  Median 1.5 1.5 1.5
  Range 0.3–2.0 0.3–2.0 0.3–2.0
Pleural invasion 0.47
  Absent 364 (89) 229 (89) 135 (87)
  Present 47 (11) 27 (11) 20 (13)
Lymphatic invasion 0.002
  Absent 277 (67) 187 (73) 90 (58)
  Present 134 (33) 69 (27) 65 (42)
Vascular invasion 0.043
  Absent 319 (78) 207 (81) 112 (72)
  Present 92 (22) 49 (19) 43 (28)
Lepidic pattern <0.001
  Absent 158 (38) 80 (31) 78 (50)
  Present 253 (62) 176 (69) 77 (50)
Acinar pattern 0.15
  Absent 15 (4) 12 (5) 3 (2)
  Present 396 (96) 244 (95) 152 (98)
Papillary pattern <0.001
  Absent 112 (27) 88 (34) 24 (15)
  Present 299 (73) 168 (66) 131 (85)
Micropapillary 
pattern
<0.001
  Absent 205 (50) 178 (70) 27 (17)
  Present 206 (50) 78 (30) 128 (83)
Solid pattern 0.001
  Absent 263 (64) 179 (70) 84 (54)
  Present 148 (36) 77 (30) 71 (46)
Significant P values are shown in bold.
STAS, spread through air spaces.
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were interconnected with each other and with the main tumor 
using reconstructed 3D images of serial-sectioned slides, 
thereby suggesting tumor islands may have been another pat-
tern of tumor infiltration into the lung parenchyma. Whether 
this is true for the micropapillary or single cell patterns of 
STAS, particularly for tumor cells found over 1 cm away from 
the tumor edge is not clear. Rare cases of lung adenocarci-
nomas with tumor cells in air spaces within the main tumor 
have been reported noting a pattern resembling desquamative 
interstitial pneumonia.28,29 However, this pattern differs from 
STAS which is present in airspaces outside the main tumor 
rather than within it. The reports of a desquamative intersti-
tial pneumonia pattern resemble the single cell discohesive 
pattern of STAS that occurred outside the main tumor, and 
raised the differential diagnosis of between the tumor cells of 
STAS and alveolar macrophages. Key points on how to dis-
tinguish STAS from artifacts and alveolar macrophages were 
outlined in our methods. If this distinction is difficult based 
on morphological criteria, immunohistochemistry for keratin 
and a macrophage marker such as CD68 may be helpful. The 
finding that STAS is an independent predictor of recurrence 
suggests this is clinically important and it does not represent 
an artifact.
In this study, we identified that the tumor STAS pattern 
was independently associated with high risk of recurrence in 
patients undergoing limited resection but not in those under-
going lobectomy. More interestingly, the STAS pattern was 
a significant risk factor for locoregional recurrence, suggest-
ing these occult tumor cells, which are invisible grossly after 
FIGURE 2.  Distance of tumor STAS from edge of main tumor. A, Distance between tumor surface and farthest STAS away from 
the tumor edge was measured by a ruler with a median of 1.5 mm (range 0.2–8.5 mm), and (B) according to number of alveolar 
spaces with a median of 7 (range 1–58). STAS, spread through air spaces.
FIGURE 3.  CIR by STAS in the limited resection group. A, CIR for any recurrence of patients with STAS-positive tumors was 
significantly higher than for patients with STAS-negative tumors (5-year CIR, 42.6% vs. 10.9%; P < 0.001). B, CIR for distant 
recurrence of patients with STAS-positive tumors was significantly higher than for patients with STAS-negative tumors (5-year 
CIR, 20.4% vs. 6.8%; P = 0.035). C, CIR for locoregional recurrence of patients with STAS-positive tumors was significantly 
higher than for patients with STAS-negative tumors (5-year CIR, 22.2% vs. 4.1%; P = 0.001). STAS, spread through air spaces; 
CIR, cumulative incidence of recurrence.
TABLE 3.  Multivariate Analysis for Recurrence in the Limited 
Resection Group
Variables HR 95% CI P
Age, years: ≥65 vs. <65 0.50 0.24 to 1.05 0.068
Tumor size, cm: >1 vs. ≤1 4.00 0.90 to 17.80 0.069
Vascular invasion: present 
vs. absent
2.10 0.97 to 4.56 0.061
STAS: present vs. absent 3.08 1.26 to 7.56 0.014
Significant P value is shown in bold.
HR, hazard ratio; CI, confidence interval; STAS, spread through air spaces.
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limited resection, may result in positive surgical margins after 
limited resection. However, because this was a retrospective 
review of cases, it was very difficult to evaluate the status 
of tumor STAS in the surgical margins. We also had insuf-
ficient data to calculate the significance of differing amounts 
of STAS. We measured the distance from the tumor surface 
to the farthest tumor STAS; however, our specimens were not 
consistently inflated making these measurements challeng-
ing. Therefore, further investigation is warranted to study 
the clinical impact of confirming whether surgical margins 
are microscopically free of the tumor STAS pattern in lim-
ited resection specimens and whether the tumor STAS pattern 
can be detected on frozen sections during surgery. This may 
help thoracic surgeons make clinical decisions on additional 
treatments, intraoperatively and postoperatively. In addition, 
further studies are required to determine whether or not the 
extent of tumor STAS, in terms of circumference involved 
or distance from the tumor edge, is associated with disease 
recurrence. Defining the edge of the tumor may be difficult in 
some cases particularly with a significant micropapillary com-
ponent; however, in most cases this can be achieved. Tumor 
cells identified as STAS beyond the border of the tumor should 
not be included in the comprehensive histologic subtyping of 
lung adenocarcinomas as they represent a pattern of invasion. 
It is possible that one of the reasons why small percentages 
(5%) of a micropapillary pattern in lung adenocarcinomas 
have been reported to correlate with poor prognosis may be 
because these actually represented micropapillary STAS.7,16 
This also needs to be investigated in future studies.
The most important clinical implication of finding 
STAS in a resection specimen is the possibility of a positive or 
close margin that might easily be missed by pathologists who 
do not specifically look for this lesion. Our data suggested that 
presence of STAS was particularly important in patients who 
had undergone limited resections for lung adenocarcinoma. 
Lobectomy with hilar and mediastinal lymph node dissec-
tion was the current standard procedure for treatment of early 
stage lung cancers, whereas multiple studies have suggested 
that peripheral small (less than or equal to 2 cm) lung cancers 
could be treated by limited resection alone; this technique may 
be as effective as a lobectomy with the added advantage of 
preserving lung function.30–32 With recent randomized trials 
assessing low-dose computed tomography screening for lung 
cancers,33–35 it is anticipated that an increasing number of 
patients will be diagnosed with early stage small lung ade-
nocarcinomas. Despite this, there have been no established 
criteria for choosing limited resection over lobectomy for the 
treatment of lung adenocarcinomas to date.
The micropapillary pattern has been reported to be a 
high-grade morphologic pattern in lung adenocarcinoma and 
was associated with lymphovascular invasion.15,16,36,37 In our 
study, STAS was more frequently identified in cases that had 
a micropapillary pattern in the main tumor. However, for ade-
nocarcinoma subtyping the micropapillary pattern is assessed 
only within the borders of the tumor edge, whereas STAS 
represents a pattern of invasion within surrounding airspaces 
beyond the edge of the tumor. Although the STAS pattern was 
also positively associated with the presence of lymphovas-
cular invasion, which has been considered a significant poor 
prognostic factor, tumor STAS was an independent risk factor 
of recurrence in the limited resection group, whereas vascular 
invasion was not. Our group has recently demonstrated that 
the presence (greater than or equal to 5%) of micropapillary 
pattern identified a high-risk group for recurrence among 
patients who underwent limited resection but not those who 
underwent lobectomy,7 thereby suggesting that patients whose 
tumors were pathologically diagnosed as having micropapil-
lary pattern after limited resection may benefit from comple-
tion lobectomy.
In conclusion, we have shown that STAS pattern is a 
significant risk factor of disease recurrence in small (less than 
or equal to 2 cm) stage I lung adenocarcinoma treated with 
limited resection. This supports our proposal that STAS be 
formally recognized as a pattern of invasion in lung adeno-
carcinoma. Although we did not study STAS in other histo-
logic types of lung cancer, we have seen it in our clinical work 
and prior literature suggests that it occurs in other histologies 
such as squamous cell carcinoma.25 Furthermore, based on 
this observation, in the future it is possible for patients who 
undergo limited resection that the identification of STAS may 
help clinicians make better clinical decisions on postopera-
tive therapies, such as adjuvant chemotherapy and comple-
tion of lobectomy with lymph node dissection. Hopefully, our 
findings will encourage further investigations to determine 
FIGURE 4.  CIR by STAS in the lobectomy group. 
A, The presence of tumor STAS was not associated 
with risk of any recurrence compared with absence 
of STAS (5-year CIR, 12.7% vs. 9.5%; P = 0.50). B, 
The presence of tumor STAS was not associated with 
risk of distant recurrence compared with absence of 
STAS (5-year CIR, 9.6% vs. 7.6%; P = 0.76). STAS, 
spread through air spaces; CIR, cumulative inci-
dence of recurrence.
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whether the tumor STAS pattern is microscopically recogniz-
able on frozen sections of lung adenocarcinoma, which may 
help thoracic surgeons choose lobectomy over limited resec-
tion for appropriate patients intraoperatively. In addition, 
the issues in surgical margin by tumor STAS, especially in 
limited resection cases, should be investigated and resolved 
in the prospective studies in the future. Further study is also 
needed at the molecular level to better understand what are 
the genetic and biological characteristics of tumor cells that 
make them prone to loss of cohesiveness and spread through 
air spaces.
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ERRATUM
9q33.3, A Stress-Related Chromosome Region, Contributes to Reducing Lung Squamous Cell Carcinoma Risk: Erratum
The name of the first author of the article beginning on page 1041 of the July 2014 issue appeared incorrectly as Qin Xiao, MA. The correct author list is:
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In addition, supporting information regarding this article can be found online at http://links.lww.com/JTO/A824.
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